Introduction {#s1}
============

*Klebsiella pneumoniae* is a Gram-negative pathogen which causes suppurative lesions, bacteremia, and urinary as well as respiratory tract infections mostly in patients with underlying diseases [@pone.0054430-Podschun1]. In Asian countries, especially in Taiwan and Korea, *K. pneumoniae* is the predominant pathogen responsible for pyogenic liver abscess in diabetic patients [@pone.0054430-Han1], [@pone.0054430-Lau1], [@pone.0054430-Yang1]. In recent years, reports of *Klebsiella* liver abscess (KLA) in western countries have also been accumulating [@pone.0054430-Lederman1]. Among the virulence factors identified in *K. pneumoniae*, capsular polysaccharide (CPS) is considered as the major determinant for *K. pneumoniae* virulence. Pyogenic liver abscess isolates often carry heavy CPS loads that could protect the bacteria from phagocytosis and killing by serum factors [@pone.0054430-Sahly1], [@pone.0054430-Lin1]. The capsular serotypes of *K. pneumoniae* have been classified into more than 77 known types [@pone.0054430-Fung1], [@pone.0054430-Pan1]. In Taiwan, a high prevalence of the K1 and K2 serotypes of *K. pneumoniae* was documented in liver abscess of diabetes mellitus patients [@pone.0054430-Fung2]. However, the exact mechanism of the tight association between *K. pneumoniae*, liver abscess, and diabetes mellitus remains unclear.

Diabetic patients have been reported to be more susceptible to infections [@pone.0054430-Geerlings1], [@pone.0054430-Patterson1]. It has also been demonstrated that *K. pneumoniae* strains are more virulent in diabetic than in normal mice [@pone.0054430-Wu1]. The increased risk of bacterial infection in diabetic patients has been studied with regard to host immune system defects [@pone.0054430-Muller1], [@pone.0054430-Peleg1], [@pone.0054430-Chen1]; however, the alteration of gene expression patterns of pathogenic bacteria in response to elevated blood glucose levels awaits further investigation. First studied in *Escherichia coli* but highly conserved across bacteria, the carbon catabolite repression (CCR) regulates uptake of glucose and repression of genes required for utilization of less preferred carbon sources [@pone.0054430-Botsford1], [@pone.0054430-Deutscher1], [@pone.0054430-McDonough1]. The CCR is generally controlled by the second messenger cyclic AMP (cAMP), which has a fundamental role in global gene regulation [@pone.0054430-Saier1]. Bacteria grown in glucose show inhibited cAMP production, while bacteria grown in less-preferred carbon sources produce elevated levels of cAMP [@pone.0054430-Botsford1], [@pone.0054430-McDonough1], [@pone.0054430-Peterkofsky1]. To balance intracellular cAMP levels, the adenylate cyclase CyaA and the cAMP phosphodiesterase CpdA, are required for cAMP biosynthesis and degradation, respectively [@pone.0054430-Botsford1], [@pone.0054430-McDonough1], [@pone.0054430-Imamura1], [@pone.0054430-Kim1]. The cellular target for cAMP signalling is the cAMP receptor protein (CRP). To regulate mRNA transcription, CRP consists of a homodimer with cAMP and exhibits DNA-binding activity to the CRP binding site (TGTGA-N6-TCACA and TGCGA-N6-TCGCA) in promoter regions [@pone.0054430-Berg1], [@pone.0054430-Harman1], [@pone.0054430-Cameron1], [@pone.0054430-Ebright1]. In *E. coli*, CRP-cAMP acts as a global regulator of gene expression by controlling the expression of almost 200 operons [@pone.0054430-Gosset1], [@pone.0054430-MartinezAntonio1], [@pone.0054430-Zheng1]. In addition to the regulation of carbon metabolism genes, cAMP signalling has been demonstrated to regulate the expression of various genes encoding virulence factors, such as flagella, fimbriae, protease, exotoxin, and secretion systems in bacteria [@pone.0054430-Baga1]--[@pone.0054430-Stella1].

Sequence analysis revealed a high similarity between CCR proteins (CyaA, CpdA, and CRP) in *E. coli* and *K. pneumoniae*, suggesting a conserved regulatory mechanism. In the previous study, CRP-cAMP has been demonstrated to regulate the expression of citrate fermentation genes in *K. pneumoniae* under fermentative conditions [@pone.0054430-Meyer1]. However, the role of CCR proteins in *K. pneumoniae* pathogenesis is large uncharacterized. In this study, we aimed to examine the effect of glucose levels and CCR proteins on the regulation of *K. pneumoniae* CPS biosynthesis. Individual strains of *K. pneumoniae* CG43, a highly virulent liver abscess isolate of the K2 serotype, in which *cyaA*, *cpdA*, and *crp* had been deleted were constructed for the assessment of CPS production, and the regulatory mechanism of cAMP-dependent CCR in *cps* transcription was analysed.

Results {#s2}
=======

Glucose Stimulates CPS Biosynthesis {#s2a}
-----------------------------------

To analyse if exogenous glucose affects *K. pneumoniae* CPS biosynthesis, CG43S3 was grown in LB broth supplemented with increasing amount of glucose for the quantification of CPS. As shown in [Fig. 1](#pone-0054430-g001){ref-type="fig"}, the CPS level increased when bacteria were grown in LB broth supplemented with 0.25% and 0.5% glucose, while the addition of 0.1% glucose did not have an obvious effect. Since the presence of glucose in the growth medium has been demonstrated to inhibit the cAMP production in many bacteria [@pone.0054430-Botsford1], [@pone.0054430-Peterkofsky1], we examined whether the elevated CPS production was regulated by cAMP. Increasing amounts of exogenous cAMP were added to LB broth supplemented with 0.5% glucose, and bacterial CPS production was determined. The result showed that the addition of exogenous cAMP repressed the effect of glucose on CPS production, suggesting that environmental glucose can activate *K. pneumoniae* CPS biosynthesis through a reduction of cAMP level.

![Glucose and cAMP affects the CPS levels of *K. pneumoniae* CG43S3.\
CPS levels of *K. pneumoniae* CG43S3 were activated by increasing environmental glucose. Bacterial strains were grown in LB broth supplemented with glucose and cAMP as indicated at 37°C with agitation. After 16 h of growth, the bacterial glucuronic acid content was determined. \**P*\<0.05 and \*\**P*\<0.01 compared with no addition. \#*P*\<0.05 compared to the indicated group.](pone.0054430.g001){#pone-0054430-g001}

CCR Proteins Affect CPS Biosynthesis {#s2b}
------------------------------------

To confirm that *K. pneumoniae* CPS biosynthesis is regulated by cAMP, individual strains with deletion of *cyaA* and *cpdA*, which respectively encodes adenylate cyclase and cAMP phosphodiesterase from CG43S3, were constructed, and the effects of the deletions on CPS production were analysed. As shown in [Fig. 2A](#pone-0054430-g002){ref-type="fig"}, compared to wild type (WT) strain, we found that CPS levels increased in Δ*cyaA*, and introduction of pcyaA, but not the empty vector control (pACYC184), into Δ*cyaA* could reverse the effect of *cyaA* mutation. In contrast, the deletion of *cpdA* caused a decreased in CPS levels, which could be complemented by introducing a plasmid-carried *cpdA* (pETQ-*cpdA*) into the Δ*cpdA* strain. These results confirmed that cAMP can act as a signalling molecule for regulation of CPS biosynthesis. In addition, since cAMP affects gene transcription through its effector protein CRP, we assessed the effect of deletion of *crp* on CPS levels. As shown in [Fig. 2B](#pone-0054430-g002){ref-type="fig"}, compared to WT, Δ*crp* produced higher levels of CPS. [Introduction](#s1){ref-type="sec"} of the complement plasmid p*crp*, but not the empty vector control (pACYC184), into Δ*crp* reversed the effect of the deletion. This result indicates that the CRP-cAMP signalling pathway is involved in the regulation of CPS biosynthesis, and that CRP acts as a negative regulator of CPS biosynthesis. In addition, since the functions of CyaA, CpdA, and CRP in controlling the cAMP level in *K. pneumoniae* have not yet been demonstrated, enzyme-linked immunosorbent assays were performed to determine the intracellular cAMP level upon the deletion of *cyaA*, *cpdA*, or *crp*. Compared to WT (9.75±0.35 nM), the intracellular cAMP level was almost undetectable in Δ*cyaA* (\<1 nM), whereas a higher cAMP level was found in Δ*cpdA* (38±2.8 nM) ([Fig. 2C](#pone-0054430-g002){ref-type="fig"}). In addition, a slight increase in the cAMP level was found in Δ*crp* (14.5±0.7 nM). These result confirmed that CyaA and CpdA are responsible for cAMP biosynthesis and degradation, respectively, in *K. pneumoniae*.

![CCR proteins affect bacterial CPS levels.\
(A) CPS levels of WT, Δ*cyaA*, Δ*cpdA* strains and complementation of *cyaA* and *cpdA* strains were determined. (B) CPS levels in mutation and complementation of *crp* strains were determined. Bacteria were grown in LB medium at 37°C with agitation. \**P*\<0.05 and \*\**P*\<0.01 compared to the indicated group. (C) Intracellular levels of cAMP in WT, Δ*cyaA*, Δ*cpdA*, and Δ*crp* strains, as determined by ELISA. The results shown are an average from triplicate measurements in one single experiment representative of three independent experiments. Error bars indicate standard deviations. \**P*\<0.05 and \*\**P*\<0.01 compared with WT.](pone.0054430.g002){#pone-0054430-g002}

Effect of cAMP-dependent CCR on *cps* Transcription {#s2c}
---------------------------------------------------

The K2 *cps* gene cluster of *K. pneumoniae* Chedid contains 19 open reading frames (ORFs) organised into 3 transcription units, namely, *orf1--2*, *orf3--15*, and *orf16--17* [@pone.0054430-Arakawa1]. To investigate the effect of glucose and cAMP-related proteins on the expression of the 3 *cps* gene clusters, the mRNA level of *orf1* (named *galF*), *orf3* (named *wzi*), and *orf16* (named *manC*) were measured by qRT-PCR in WT grown in LB medium containing 0.5% glucose with or without 1 mM cAMP. In addition, the effect of *cyaA*, *cpdA*, and*crp* mutation strains on the mRNA levels of *galF*, *wzi*, and *manC* were also determined. As shown in [Fig. 3A](#pone-0054430-g003){ref-type="fig"}, we found that the mRNA levels of *galF*, *wzi* and *manC* was increased in glucose-rich medium (LB+0.5% glucose), whereas addition of 1 mM cAMP to the glucose-rich medium could restore the *galF*, *wzi* and *manC* expression, similar to the trends observed in the WT strain. Furthermore, the mRNA levels of *galF*, *wzi*, and *manC* revealed an apparent increase in the Δ*cyaA* and Δ*crp* strains as compared to that observed in the WT strain. In contrast, a slight reduction in the mRNA level of *cps* genes was found in the Δ*cpdA* strain. This result indicates that *cps* mRNA expression is regulated by cAMP-dependent CCR, and CRP may acts a repressor of *cps* expression.

![Glucose and CCR proteins affect *cps* transcription.\
(A) qRT-PCR analyses of the expression of the K2 *cps* genes (*orf1*, *orf3*, and *orf16*) for WT, Δ*cyaA*, Δ*cpdA*, and Δ*crp* strains in LB or indicated LB medium. (B) β-galactosidase activities of *K. pneumoniae* CG43S3Δ*lacZ* and the isogenic strain (Δ*lacZ*Δ*crp*) carrying the reporter plasmid pOrf12 (P*~orf1-2~*::*lacZ)*, pOrf315 (P*~orf3-15~*::*lacZ*), or pOrf1617 (P*~orf16-17~*::*lacZ)* were determined using log-phase cultures grown in LB medium. The results shown are an average from triplicate measurements in one single experiment representative of three independent experiments. Error bars indicate standard deviations. \**P*\<0.05 and \*\**P*\<0.01 compared to the indicated group.](pone.0054430.g003){#pone-0054430-g003}

To further confirm whether CRP acts as a transcriptional repressor of the promoter activity of *galF*, *wzi*, and *manC*, the reporter plasmids pOrf12 (P*~orf1-2~*::*lacZ*), pOrf315 (P*~orf3-15~*::*lacZ*), and pOrf1617 (P*~orf16-17~*::*lacZ*), each carrying a *lacZ* reporter gene transcriptionally fused to the putative promoter region of the K2 *cps* gene cluster [@pone.0054430-Lin2], were used to transform the *K. pneumoniae* strains CG43S3Δ*lacZ* and Δ*lacZ*Δ*crp*. The promoter activity measurements shown in [Fig. 3B](#pone-0054430-g003){ref-type="fig"} revealed that the deletion of *crp* in the Δ*lacZ* strain apparently increased the promoter activities of *galF*, *wzi*, and *manC*. These results verify that CRP represses *cps* expression at the transcriptional level.

Determination of Transcriptional Start Sites on 3 Transcriptional Units in the K2 *cps* Gene Cluster {#s2d}
----------------------------------------------------------------------------------------------------

Until now, the transcriptional start sites of the *cps* gene cluster had not been characterized. 5′ rapid amplification of cDNA ends (5′ RACE) was first performed to determine the transcriptional start sites of the 3 transcription units in the K2 *cps* gene cluster. A single DNA band was obtained for *galF*, *wzi*, and *manC* from the 5′ RACE analysis using either primer pair (data not shown). As shown in [Fig 4A, B, and C](#pone-0054430-g004){ref-type="fig"}, sequence analysis of a total of 10 clones each from *galF*, *wzi*, and *manC* revealed a transcriptional start site at the A nucleotide at position −61 relative to the translational start site of *galF*, at the G nucleotide at position −470 relative to the translational start site of *wzi*, and at the G nucleotide at position −56 relative to the translational start site of *manC*. The conserved −10 and −35 promoter sequence of σ70 could be readily identified and is shown in [Fig 4](#pone-0054430-g004){ref-type="fig"}.

![Identification of the transcriptional start sites of 3 transcriptional units in the K2 *cps* gene cluster by 5′ RACE.\
The 5′ RACE experimental design for *galF* (A), *wzi* (B), and *manC* (C). Relative positions of the primers used and the expected size of the PCR product are indicated. The transcriptional start site is marked as +1 and underlined. The potential −10, −35, and ribosomal binding sites (RBS) are underlined. The grey box indicates the predicted RcsAB box. The dashed boxes indicate the predicted CRP binding sites. (D) The predicted CRP binding sites in P*~wzi~* and P*~manC~* are aligned against each other. \#, the position is relative to the transcriptional start site.](pone.0054430.g004){#pone-0054430-g004}

To further investigate the mechanism of CRP-cAMP regulation of *cps* gene transcription, the sequences of the *E. coli* CRP binding sites (TGTGA-N6-TCACA and TGCGA-N6-TCGCA) were used in searching the promoter sequence of the K2 *cps* gene cluster of *K. pneumoniae* Chedid. The maximum number of possible mismatched nucleotides was set at 3, and only the intergenic regions of the 3 transcriptional units were analysed in this search. Using these criteria, no typical CRP binding sites were located the upstream of *galF* ([Fig. 4A](#pone-0054430-g004){ref-type="fig"}). However, 3 CRP binding sites were found in the sequence upstream of *wzi* ([Fig. 4B](#pone-0054430-g004){ref-type="fig"}), and one CRP binding site was found to be located at position −140 to −125 relative to the transcriptional start site of *manC* ([Fig. 4C and D](#pone-0054430-g004){ref-type="fig"}). Among the 3 CRP binding sites were located in the intergenic regions of *orf2* and *wzi*, one was located in the 5′ mRNA region that is 137 bp upstream of the translation start site of Wzi (at position +319 to +344 relative to the transcriptional start site of *wzi*), the other 2 CRP binding sites were found to be located at position −29 to −14 and −87 to −72 relative to the transcriptional start site of *wzi* ([Fig. 4D](#pone-0054430-g004){ref-type="fig"}). The result implies that CRP could bind directly to the CRP binding sites that are located in P*~wzi~* and P*~manC~* for controlling *cps* expression.

CRP Directly Binds to the CRP Binding Sites in P*~wzi~* and P*~manC~* {#s2e}
---------------------------------------------------------------------

To demonstrate whether CRP binds directly to the upstream sequence of *wzi* and *manC* via the CRP binding sites, electric mobility shift assay (EMSA) was performed using the recombinant His~6~-CRP protein and different DNA fragments containing truncated forms of Pwzi (Pwzi-1, Pwzi-2, Pwzi-3, and Pwzi-4) and PmanC (PmanC-1 and PmanC-2), as described in the Materials and Methods. Using Pwzi fragments of different lengths, binding of His~6~-CRP could be observed for Pwzi-1, Pwzi-2, and Pwzi-3 but not for Pwzi-4 ([Fig. 5A](#pone-0054430-g005){ref-type="fig"}). As shown in [Fig. 5A](#pone-0054430-g005){ref-type="fig"}, DNA-protein-binding complexes were observed after the incubation of 100 nM purified His~6~-CRP with 10 ng Pwzi-1 or Pwzi-2. However, formation of the Pwzi-3/CRP complex required the incubation with 200 nM purified His~6~-CRP. This suggests that the lower binding ability of His~6~-CRP in Pwzi-3 is due to the location of only one CRP binding site in Pwzi-3 as compared to 2 and 3 CRP binding sites in Pwzi-1 and Pwzi-2, respectively. In addition, we found that His~6~-CRP was able to bind to the PmanC-1 DNA fragment, but not to the PmanC-2 fragment in which the CRP binding site had been removed ([Fig. 5B](#pone-0054430-g005){ref-type="fig"}). This result indicates that the recombinant His~6~-CRP protein can bind directly to the predicted CRP binding sites located in P*~wzi~* and P*~manC~*.

![CRP directly binds to P*~wzi~* and P*~manC~*.\
Diagrammatic representation of the *wzi* loci (P*~orf3-15~*) (A) and the *manC* loci (P*~orf16-17~*) (B). The large arrows represent the open reading frames. The relative positions of the primer sets used in PCR-amplification of the DNA probes are indicated, and the numbers denote the positions relative to the translational start site. Names of the DNA probes are shown on the left. The dashed boxes indicate the predicted CRP consensus sequences. Different concentrations of purified His~6~-CRP were incubated with 10 ng of various truncated DNA fragments of the upstream regions of *wzi* or *manC*. Following incubation at room temperature for 30 min, the mixtures were analyzed on a 5% non-denaturing polyacrylamide gel containing 200 µM cAMP. The gel was stained with SYBR Green I dye and photographed.](pone.0054430.g005){#pone-0054430-g005}

Expression of *rcsA* is Controlled by cAMP-dependent CCR and Directly Repressed by CRP {#s2f}
--------------------------------------------------------------------------------------

Because no CRP binding site was found in the sequence upstream of *galF*, the expression of *galF* also appeared to be controlled by cAMP-dependent CCR, implying that CRP repression of *galF* transcription is indirect and that other transcription factors are involved in the CRP regulon controlling *cps* transcription. According to previous studies, multiple regulatory proteins, which include Fur, RcsA, RcsB, RmpA, RmpA2, KvgA, and KvhR have been shown to mediate K2 *cps* expression [@pone.0054430-Lin2], [@pone.0054430-Cheng1], [@pone.0054430-Lai1], [@pone.0054430-Lin3]. To further investigate whether these *cps* regulatory proteins are involved in CRP regulon, the CRP binding site was searched in the upstream sequence of *fur*, *rcsA*/*B*, *rmpA*/*A2*, *kvgA*, and *kvhR*. However, we found the 2 CRP binding sites (rcsA-1 and rcsA-2) are located at −192 to −177 and −40 to −25 relative to the translation start site of RcsA ([Fig. 6A](#pone-0054430-g006){ref-type="fig"}), but no typical CRP binding site was found in other upstream sequence of *fur*, *rcsB*, *rmpA*/*A2*, *kvgA*, and *kvhR*. Therefore, we suggest that RcsA is a CRP-regulated transcription factor and is involved in cAMP-dependent CCR control of *cps* expression.

![Glucose and cAMP-related proteins affect *rcsA* transcription.\
(A) Diagrammatic representation of *rcsA* loci. The large arrows represent the open reading frames. The relative positions of the primer sets used in PCR amplification of the DNA probes are indicated, and the numbers denote the positions relative to the translational start site. Names of the DNA probes are shown on the left. The dashed boxes indicate the predicted CRP binding sites and the alignment is shown below. (B) qRT-PCR analysis of *rcsA* expression was measured in WT, Δ*cyaA*, Δ*cpdA*, and Δ*crp* strains in LB or indicated LB medium. The results shown are an average from triplicate measurements in one single experiment representative of three independent experiments. Error bars indicate standard deviations. \**P*\<0.05 and \*\**P*\<0.01 compared with WT. (C) The β-galactosidase activities of *K. pneumoniae* CG43S3Δ*lacZ* and the isogenic strain (Δ*lacZ*Δ*crp*) carrying the reporter plasmid prcsAZ15 (P*~rcsA~*::*lacZ*) were determined using log-phased cultures grown in LB medium. \*\**P*\<0.01 compared with Δ*lacZ*. (D) CRP binds directly to P*~rcsA~*. Different concentrations of purified His~6~-CRP were incubated with 10 ng of various truncated DNA fragments of the upstream region of *rcsA*. Following incubation at room temperature for 30 min, the mixtures were analyzed on a 5% non-denaturing polyacrylamide gel containing 200 µM cAMP. The gel was stained with SYBR Green I dye and photographed.](pone.0054430.g006){#pone-0054430-g006}

To verify this possibility, the effect of glucose and cAMP-dependent CCR on the mRNA level of *rcsA* was first determined by qRT-PCR. As shown in [Fig. 6B](#pone-0054430-g006){ref-type="fig"}, addition of 0.5% glucose to LB medium apparently increased the mRNA level of *rcsA*, while addition of exogenous 1 mM cAMP to glucose-rich medium could restore the level of *rcsA* expression level to the same as that observed in the WT strain. In addition, the mRNA level of *rcsA* increased in the Δ*cyaA* strain, while the deletion of *cpdA* reduced on *rcsA* expression. This result indicates that *rcsA* expression is controlled by the intracellular cAMP level in response to exogenous glucose. In addition, the deletion of *crp* also increased the expression of *rcsA*, suggesting that CRP acts a transcriptional repressor of *rcsA* expression. Furthermore, measurement of promoter activity confirmed the suggestion that the deletion of *crp* caused a higher level of expression of P*~rcsA~* ([Fig. 6C](#pone-0054430-g006){ref-type="fig"}).

To further investigate whether CRP binds directly to the *rcsA* promoter region, EMSA was performed. As shown in [Fig. 6D](#pone-0054430-g006){ref-type="fig"}, DNA-protein binding complexes were observed after the incubation of 100 nM purified His~6~-CRP with 10 ng PrcsA-1, but not with PrcsA-2 in which one of the CRP binding sites was removed. Therefore, we suggested that CRP-cAMP binds directly to the CRP binding site (rcsA-1) in P*~rcsA~* to repress *rcsA* transcription.

Role of RcsA in Regulation of CRP on CPS Biosynthesis {#s2g}
-----------------------------------------------------

To understand whether RcsA participates in CRP regulation of CPS biosynthesis, the level of CPS was determined in WT, Δ*rcsA*, Δ*crp*, and Δ*crp*Δ*rcsA* strains. As shown in [Fig. 7A](#pone-0054430-g007){ref-type="fig"}, the deletion of *rcsA* resulted in a slight reduction in CPS level as compared to WT strain. However, the deletion of *rcsA* partially restored CPS production in the Δ*crp* strain. In addition, introducing the complementary plasmid p*rcsA* into the Δ*crp*Δ*rcsA* strain increased CPS levels as compared to the strain carrying the empty vector control (pRK415). These results indicate that RcsA participates in CRP regulation of CPS biosynthesis.

![RcsA is involved in CRP regulation of CPS expression.\
(A) CPS levels of WT, Δ*rcsA*, Δ*crp*, and Δ*crp*Δ*rcsA* strains were determined. For complementation purposes, introduction of pRK415 and prcsA into Δ*crp*Δ*rcsA* strain were also determined. Bacterial strains were grown in LB broth as indicated at 37°C with agitation. After 16 h of growth, the bacterial glucuronic acid content was determined. \**P*\<0.05 and \*\**P*\<0.01 compared to the indicated group. (B) The β-galactosidase activities of *K. pneumoniae* CG43S3Δ*lacZ* and the isogenic strains (Δ*lacZ*Δ*crp*, Δ*lacZ*Δ*rcsA*, and Δ*lacZ*Δ*crp*Δ*rcsA*) carrying the reporter plasmid pOrf12 (P*~orf1-2~*::*lacZ)*, pOrf315 (P*~orf3-15~*::*lacZ*), or pOrf1617 (P*~orf16-17~*::*lacZ)* were determined using log-phased cultures grown in LB medium. The results shown are an average from triplicate measurements in one single experiment representative of three independent experiments. Error bars indicate standard deviations. \**P*\<0.05 compared to the indicated group.](pone.0054430.g007){#pone-0054430-g007}

To further understand the role of RcsA in CRP regulation of *cps* transcriptions, the promoter activity of *galF* (pOrf12), *wzi* (pOrf315), and *manC* (pOrf1617) was measured in Δ*lacZ*, Δ*lacZ*Δ*crp*, Δ*lacZ*Δ*rcsA*, and Δ*lacZ*Δ*crp*Δ*rcsA* strains. As shown in [Fig. 7B](#pone-0054430-g007){ref-type="fig"}, the deletion of *rcsA* in Δ*lacZ* caused an apparent reduction on the promoter activity of *galF*, but no effect on the promoter activity of *wzi* and *manC* was observed, indicating that RcsA plays a positive role in *galF* transcription. In addition, the deletion of *rcsA* in the Δ*lacZ*Δ*crp* strain caused a slight reduction in the promoter activity of *galF*, unlike that in the Δ*crp* strain, but still showed higher promoter activity than the Δ*lacZ* strain. The result implies that RcsA participates in CRP regulation of *galF* transcription. However, we suggest that other unknown transcriptional regulator(s) are also involved in this regulation.

Effect of cAMP-dependent CCR on Susceptibility to Normal Human Serum {#s2h}
--------------------------------------------------------------------

Since CPS has been demonstrated to protect *K. pneumoniae* from killing by serum factors, we suggest that glucose, cAMP, and cAMP-related proteins may also affect the ability of *K. pneumoniae*, through modulation of CPS levels, to resist the bactericidal effects of serum. To test the hypothesis, the effects of exogenous glucose and cAMP on survival rate were first determined in treatment with 75% normal human serum. We found that the survival rate of WT grown in LB supplemented with 0.5% glucose (43.2±3.9%) increased about 2-fold as compared to the survival rate of WT in LB alone (21.2±2.3%). Addition of 1 mM cAMP diminished the higher survival rate of WT when grown in LB with 0.5% glucose (34.3±0.1%). This implies that the intracellular cAMP level decreased in *K. pneumoniae* grown in LB with 0.5% glucose, which then increased the serum resistance in *K. pneumoniae*. In addition, the deletion of *cyaA* in WT apparently increased the survival rate (40.7±0.7%), while the deletion of *cpdA* reduced the survival rate (12.7±0.6%). It also confirmed that the intracellular cAMP level could affect the ability of *K. pneumoniae* to resist the bactericidal effects of serum. Finally, the deletion of *crp* in WT had a higher survival rate (28.5±1.9%) in treatments with 75% normal human serum as compared to WT strain. Thus, the results imply that *K. pneumoniae* could resist serum killing in response to higher glucose levels via the trigger of cAMP-dependent CCR.

Discussion {#s3}
==========

Clinically isolated *K. pneumoniae* strains usually produce a large amount of CPS, which confers not only a mucoid phenotype to the bacteria but also resistance to engulfment by phagocytes or to serum bactericidal factors [@pone.0054430-Lin1], [@pone.0054430-Regueiro1]. The degree of mucoidy has also been positively correlated with successful establishment of infection [@pone.0054430-Nassif1], [@pone.0054430-Nassif2]. Although CPS has been repeatedly proven to play an important role in *K. pneumoniae* infections and multiple CPS regulators have been found, the environmental stimuli that modulate CPS biosynthesis has remained largely unknown. Our previous studies have reported that extracellular ferric ion could repress *K. pneumoniae* CPS production through Fur regulation [@pone.0054430-Cheng1], [@pone.0054430-Lin3]. Moreover, in the present study, we found that environmental glucose stimulated CPS production, which was regulated by cAMP ([Fig. 1](#pone-0054430-g001){ref-type="fig"}) and CCR proteins ([Fig. 2](#pone-0054430-g002){ref-type="fig"}), resulting in an increased resistance to serum killing. These findings imply that, in response to elevated blood glucose levels in diabetic patients, *K. pneumoniae* could produce more CPS to facilitate its persistence in the blood.

In *E. coli*, the expression of *cps::lacZ* was activated when cells were grown at a low temperature (20°C) in the presence of glucose (0.4%) as a carbon source [@pone.0054430-Hagiwara1]. As shown in [Fig. 1](#pone-0054430-g001){ref-type="fig"}, in *K. pneumoniae* CG43, a K2 serotype strain, we found that higher CPS production in glucose-rich medium is dependent on reducing the intracellular cAMP concentration. In addition, the activation of CPS in response to exogenous glucose was also found in *K. pneumoniae* NTUH-K2044, a highly virulent liver abscess isolate of K1 serotype, and addition of increasing amounts of exogenous cAMP in glucose-rich medium could completely reverse the effect of glucose on CPS production ([Fig. S1](#pone.0054430.s001){ref-type="supplementary-material"}). Therefore, we suggest that the regulatory role of glucose and cAMP-dependent CCR in CPS biosynthesis is conserved in *K. pneumoniae* stains of K1 and K2 serotype. Besides, the addition of cAMP did not completely reverse the glucose-activated CPS biosynthesis in *K. pneumoniae* CG43 ([Fig. 1](#pone-0054430-g001){ref-type="fig"}), suggesting that glucose could activate CPS biosynthesis through mechanism(s) other than repression of the cAMP-CRP regulation in *K. pneumoniae* CG43, which awaits further investigations.

In bacteria, CyaA and CpdA are responsible for cAMP production and degradation [@pone.0054430-Imamura1], [@pone.0054430-Kim1]. In this study, we also found that the deletion of *cyaA* abolished the ability of cAMP to increase CPS biosynthesis, while the deletion of *cpdA* elevated the cAMP level and decreased CPS biosynthesis ([Fig. 2](#pone-0054430-g002){ref-type="fig"}). Although the Δ*crp* strain has a slightly higher cAMP level than WT, CPS production is obviously high in the Δ*crp* strain. This result indicated that cAMP-mediated repression of CPS biosynthesis is required for CRP regulatory activity. In *E. coli*, CRP can repress *cyaA* transcription to down-regulate cAMP production [@pone.0054430-Inada1]. In *K. pneumoniae*, a typical CRP binding box (5′-[TGT]{.ul}T[A]{.ul}-AATTGA-[TCAC]{.ul}G-3′) was located at −144 to −129 relative to the translation start site of *cyaA*. In addition, the mRNA level of *cyaA* increased more than 16-fold in the Δ*crp* stain, unlike that in the WT strain (data not shown), indicating that the deletion of *crp* could increase *cyaA* expression to elevate the cAMP level in *K. pneumoniae,* consistent with the findings for *E. coli*.

To further identify the regulatory mechanism of *cps* transcription, the transcriptional start sites of 3 transcriptional units in the *cps* gene cluster were first determined ([Fig. 4](#pone-0054430-g004){ref-type="fig"}). CRP binds directly to the predictive CRP binding sites and represses the transcription of *wzi* and *manC* ([Fig. 3](#pone-0054430-g003){ref-type="fig"} and [5](#pone-0054430-g005){ref-type="fig"}), while indirectly repressing the transcription of *galF* via RcsA ([Fig. 3](#pone-0054430-g003){ref-type="fig"} and [7B](#pone-0054430-g007){ref-type="fig"}). According to the position of the CRP binding site relative to RNA polymerase, the CRP-activated promoter is divided into the 3 classes in *E. coli* [@pone.0054430-Ebright1], [@pone.0054430-Lawson1], [@pone.0054430-Busby1]. However, the CRP-repressed promoter displays a greater range of binding site positions [@pone.0054430-GamaCastro1]. In *K. pneumoniae*, we found CRP could directly bind to the CRP binding site of *wzi-2* and *rcsA-1* centred at and near the -10 and −35 boxes, respectively, suggesting that CRP may interfere with RNA polymerase regulation of gene transcription ([Fig. 4D](#pone-0054430-g004){ref-type="fig"} and [6A](#pone-0054430-g006){ref-type="fig"}). However, *K. pneumoniae* CRP could also repress transcription by binding directly to the predicated CRP binding site of *manC,* which was located at a relatively long distance upstream of the −10 and −35 boxes (−140 to −125) ([Fig. 3](#pone-0054430-g003){ref-type="fig"} and [4D](#pone-0054430-g004){ref-type="fig"}). Whether other additional transcriptional factors are required for CRP repression of *manC* transcription needs further investigation.

Multiple regulators including RcsA/B, RmpA/A2, KvhA, KvgA, and Fur have been demonstrated to control the transcription of *K. pneumoniae* CPS biosynthesis genes [@pone.0054430-Lin2], [@pone.0054430-Cheng1], [@pone.0054430-Lai1], [@pone.0054430-Lin3]. In this study, we also found that *cps* transcription is regulated by cAMP-dependent CCR. In *E. coli*, CRP has been reported to regulate the expression of *fur* at the transcriptional as well as at the posttranscriptional level [@pone.0054430-Lin4], [@pone.0054430-Vecerek1], [@pone.0054430-DeLorenzo1]. In addition, functional interaction of CRP and Fur has been demonstrated to coordinate the transcriptional regulation of iron and carbon metabolism [@pone.0054430-Zhang1]. In *K. pneumoniae*, CPS biosynthesis was modulated by iron availability and Fur has been shown to repress the transcription of *rmpA/A2* and *rcsA* to control CPS biosynthesis [@pone.0054430-Lin3]. As shown in this study, the expression of *rcsA* is also regulated by glucose and cAMP-dependent CCR ([Fig. 6](#pone-0054430-g006){ref-type="fig"}). In addition, RcsA is involved in the CRP regulon in regulating *galF* expression and CPS biosynthesis ([Fig. 7](#pone-0054430-g007){ref-type="fig"}). By analysing the promoter sequence of *galF*, a typical RcsAB binding box [@pone.0054430-Wehland1] (5′-[TAAGA]{.ul}T[TATTC]{.ul}TC[A]{.ul}-3′) was found to be located at position −119 to −107 relative to the transcriptional start site of *galF*, indicating that RcsA could directly activate *galF* transcription. In addition, we noted that the deletion of *rcsA* in the Δ*lacZ*Δ*crp* strain retains a higher *galF* promoter activity compared to the Δ*lacZ* strain, implying that CRP could directly or indirectly regulate *galF* expression. Although no obvious CRP binding site was found in the promoter sequence of *galF*, an EMSA was performed to investigate whether CRP could directly bind to P*~galF~*. As shown in [Fig. S2](#pone.0054430.s002){ref-type="supplementary-material"}, DNA-protein binding complexes were observed after the incubation of 150 nM purified His~6~-CRP with 10 ng P*~galF~*, implying that CRP-cAMP could directly repress the *galF* transcription. However, the exact binding site of CRP in P*~galF~* needs to be further investigated. In addition, we also found that introduction of a plasmid carrying His6-CRP encoding gene into Δ*crp* strain could complement the effect of *crp* mutation on CPS biosynthesis ([Fig. S3](#pone.0054430.s003){ref-type="supplementary-material"}). The result confirmed that His6-CRP is functional *in vivo*. Taken together, these findings revealed a complex regulatory circuit in these CPS regulators, which then modulate the transcription of cps genes in coordination, in response to various environmental stimuli.

In *K. pneumoniae*, CPS is considered to be an important virulence factor that protects the bacteria from serum killing and phagocytosis [@pone.0054430-Sahly1], [@pone.0054430-Lin1]. In this study, cAMP-dependent CCR was demonstrated to protect *K. pneumoniae* against serum killing, and the results suggest it plays a role in the regulation of CPS production. In addition, *E. coli* strains lacking cAMP-CRP are highly resistant to reactive oxygen species (ROS) containing hydrogen peroxide (H~2~O~2~) and hypochlorous acid (HOCl) [@pone.0054430-Barth1]. Large amounts of ROS are generated by phagolysosomes to inhibit bacterial colonization and survival [@pone.0054430-Slauch1]. Therefore, we suggest that cAMP-dependent CCR in *K. pneumoniae* not only regulates CPS production to protect the bacteria from serum killing and phagocytosis, but also alters bacterial resistance to oxidative stress to enhance the survival rate in the phagosome, and we are currently working to demonstrate this possibility. In addition, CPS and adherence factors, such as type 1 and type 3 fimbriae, have been demonstrated to play important roles in biofilm formation and pathogenesis, and their expression could be co-regulated [@pone.0054430-Wu2]. Biofilms are surface-attached bacteria embedded in a self-produced matrix, composed mainly of polysaccharide, but also containing proteins and nucleic acids [@pone.0054430-Sutherland1]. Biofilm formation promotes encrustation and protects the bacteria from the hydrodynamic forces of urine flow, host defences and antibiotics [@pone.0054430-Warren1]. In *E. coli* and *Serratia marcescens*, glucose/CRP-cAMP has been described to regulate the expression of type 1 fimbriae and bacterial biofilm formation [@pone.0054430-Kalivoda1], [@pone.0054430-Muller2]; however, this regulation has not been proven in *K. pneumoniae*. Since glucose has also been described to repress *K. pneumoniae* biofilm formation [@pone.0054430-Jackson1], in addition to CPS, it is possible that glucose/CRP-cAMP is able to regulate the expression of adherence factors, which we are currently investigating.

In this study, we provide important evidence that glucose stimulates CPS biosynthesis in *K. pneumoniae* to protect the bacteria from serum killing, and cAMP-dependent CCR plays a profound regulatory role in CPS expression in response to glucose levels in the environment. In diabetes mellitus patients, the higher glucose level in the bloodstream is thought to have a major impact on bacterial virulence. We suggest that *K. pneumoniae* could evade the immune response via the regulation of cAMP-dependent CCR on CPS biosynthesis, especially during infection of diabetes mellitus patients. Future studies will include determining the role of cAMP-dependent CCR in modulating CPS biosynthesis, fimbria production, and biofilm formation in response to environmental stimuli.

Materials and Methods {#s4}
=====================

Bacterial Strains, Plasmids, and Media {#s4a}
--------------------------------------

Bacterial strains and plasmids used in this study are listed in [Table 1](#pone-0054430-t001){ref-type="table"}. Primers used in this study are list in [Table 2](#pone-0054430-t002){ref-type="table"}. Bacterial were routinely cultured at 37°C in Luria-Bertani (LB) medium supplemented with appropriate antibiotics. The antibiotics used include ampicillin (100 µg/ml), kanamycin (25 µg/ml), streptomycin (500 µg/ml), and tetracycline (12.5 µg/ml).

10.1371/journal.pone.0054430.t001

###### Bacterial strains and plasmids used in this study.

![](pone.0054430.t001){#pone-0054430-t001-1}

  Strains or plasmids                                                     Descriptions                                                      Reference or source
  ---------------------- -------------------------------------------------------------------------------------------------------------- ----------------------------
  *K. pneumoniae*                                                                                                                       
  CG43S3                                                            CG43 Sm^r^, K2 serotype                                                 [@pone.0054430-Lai2]
  NTUH-K204444                                                            K1 serotype                                                      From Dr. Jin-Town Wang
  Δ*cyaA*                                                                CG43S3Δ*cyaA*                                                           This study
  Δ*cpdA*                                                                CG43S3Δ*cpdA*                                                           This study
  Δ*crp*                                                                  CG43S3Δ*crp*                                                           This study
  Δ*rcsA*                                                                CG43S3Δ*rcsA*                                                      [@pone.0054430-Lin3]
  Δ*crp*Δ*rcsA*                                                       CG43S3Δ*crp*Δ*rcsA*                                                        This study
  Δ*lacZ*                                                                CG43S3Δ*lacZ*                                                      [@pone.0054430-Lin2]
  Δ*lacZ*Δ*crp*                                                       CG43S3Δ*lacZ*Δ*crp*                                                        This study
  Δ*lacZ*Δ*rcsA*                                                      CG43S3Δ*lacZ*Δ*rcsA*                                                       This study
  Δ*lacZ*Δ*crp*Δ*rcsA*                                             CG43S3Δ*lacZ*Δ*crp*Δ*rcsA*                                                    This study
  Δ*galU*                                                                CG43S3Δ*galU*                                                      [@pone.0054430-Lai1]
  *E. coli*                                                                                                                             
  DH5α                                      *supE44*Δ*lacU169 (f80 lacZ*ΔM15)hsdR1 *recA1 endA1 gyrA96 thi-1 relA1*                       [@pone.0054430-Hanahan1]
  BL21(DE3)                                           *F^-^ ompT hsdS~B~\[r~B~^-^m~B~^-^\]gal dcm* \[DE3\]                                  New England Biolabs
  S17-1 *λ pir*                                      *hsdR recA pro* RP4-2 \[Tc::Mu; Km::Tn*7*\] \[*λpir*\]                               [@pone.0054430-Miller1]
  Plasmids                                                                                                                              
  pKAS46                                             Ap^r^ Km^r^, positive selection suicide vector, *rpsL*                              [@pone.0054430-Skorupski2]
  yT&A                                                              Ap^r^, TA cloning vector                                                      Yeastern
  pACYC184                                                 Tc^r^Cm^r^, low copy number cloning vector                                       New England Biolabs
  pRK415                                                  Tc^r^, Broad-host-range IncP cloning vector                                      [@pone.0054430-Keen1]
  pcrp                           Cm^r^, 987-bp fragment containing the upstream and coding region of *crp* cloned into pACYC184                  This study
  pETQ                                            Km^r^, for protein expression vector containing T5 promoter                              [@pone.0054430-Keen1]
  pETQ-*cpdA*                            Km^r^, 875-bp fragment containing the coding region of *cpdA* cloned into pETQ                          This study
  placZ15                                                 Cm^r^, promoter selection vector, *lacZ* ^+^                                      [@pone.0054430-Lin2]
  prcsAZ15                            Cm^r^, 488-bp fragment containing the region upstream of *rcsA* cloned into placZ15                        This study
  pOrf12                   Cm^r^, 500-bp fragment containing the region upstream of *Klebsiella K2 cps orf1-orf2* cloned into placZ15       [@pone.0054430-Lin2]
  pOrf315                 Cm^r^, 900-bp fragment containing the region upstream of *Klebsiella K2 cps orf3-orf15* cloned into placZ15       [@pone.0054430-Lin2]
  pOrf1617                Cm^r^, 300-bp fragment containing the region upstream of *Klebsiella K2 cps orf16-orf17* cloned into placZ15      [@pone.0054430-Lin2]
  pET30b-CRP                                   Km^r^, 654-bp fragment encoding full-length CRP cloned into pET30b                                This study
  pcyaA04                          Ap^r^Km^r^, 2.0 kb fragment containing *cyaA* and its flanking regions cloned into pKAS46                     This study
  pcpdA04                          Ap^r^Km^r^, 2.0 kb fragment containing *cpdA* and its flanking regions cloned into pKAS46                     This study
  pcrp04                            Ap^r^Km^r^, 2.0 kb fragment containing *crp* and its flanking regions cloned into pKAS46                     This study
  prcsA                          Tc^r^, 1.2-kb fragment containing the upstream and coding region of *rcsA* cloned into pRK415                   This study
  pcyaA                         Cm^r^, 2918-bp fragment containing the upstream and coding region of *cyaA* cloned into pACYC184                 This study
  pETQ-His~6~-*crp*                           Km^r^, 804-bp fragment containing the His~6~-*crp* cloned into pETQ                                This study

10.1371/journal.pone.0054430.t002

###### Primers used in this study.

![](pone.0054430.t002){#pone-0054430-t002-2}

  Primer                     Sequence (5′→3′)             Enzyme cleaved    
  ----------------- ----------------------------------- ------------------- ------------
  GT131                  GGATCCTTCTACCCATTTCACACGC            *Bam*HI       
  GT132                 AAGCTTCAATACGCCGCTTAGCAACTT          *Hin*dIII      
  GT137                  GGATCCCATGGTGCTTGGCAAACC             *Bam*HI       
  GT140                   GGATCCCAACCGGGTATAGCTG              *Bam*HI       
  GT141                AGATCTCCGGTTCTTGACTTTACTTTAAG          *Bgl*II       
  GT145                   CATAAAGATCTACCTGTACGCA              *Bgl*II       
  GT154                 GGATCCAGCCATAATCACAGGAAGCAA           *Bam*HI       
  GT157                   GGATCCCAGGGAGGAAAGCAAA              *Bam*HI       
  GT159                AGATCTGGCAGATATTCGGTAACAACAC           *Bgl*II       
  GT160                  AGATCTTTATATGCCGCCCGAGTC             *Bgl*II       
  GT161                  AGATCTTGTTTCCTCTCCTTCGTTG            *Bgl*II       
  GT162                AGATCTGCTTAGGGTAAATGTACTTGCC           *Bgl*II       
  GT163                  AGATCTTAATTGGTGACCCGCTTAT            *Bgl*II       
  GT167                    GGCCTGACCAATTATTCATCC                            
  GT171                GTTGTTCGACAGCTTATTGAGCTGGCGC                         
  GT172                 GTCTAGATCCGGTAGTGGAAATCCAGA           *Xba*I        
  GT173                  GAATTCAACCTGCCGCAGTTCTATC            *Eco*RI       
  GT174                    GAATTCCACGCCGAGCGAGGC              *Eco*RI       
  GT175                  CCCTTCGAGCATGGCGAGCTCTAAC            *Sac*I        
  GT179                  AATCTCTTTGATCCCGGCGGCGACG                          
  GT192                 TCGGTTGAAGTGTAGCCGGTAACCCGG                         
  GT196                 CGGATCCGTCATTATCGACCACTATCC           *Bam*HI       
  GT197                  CAAGCTTATCCGGGCCAAATCTACG           *Hin*dIII      
  GT200                    TCAGCGGCTCGTTCCTTTGC                             
  GT202                  CGGATCCAAATGGTGTCCTTAGGT             *Bam*HI       
  GT203                 GGGATCCTTCAGAAGGCTACTGATGGC           *Bam*HI       
  GT204                  GTCTAGACGTGCAGGTCTTCCACTT            *Xba*I        
  GT205                  GGAGCTCGATTTATACCGTTTTCG             *Sac*I        
  GT210                    ATGCAGATAAAGGAGCGTCGC                            
  GT211                 GGGATCCGTCGTTAAACCTAAGGACAC           *Bam*HI       
  GT227                 GATATCATGCACCATCATCATCATCAT           *Eco*RI       
  CC348                   TTACCCCGCAATTTTCCCGCAC                            
  CC349               CTCGAGGGTAGGGTCTGTTTGCGGTTTGCC          *XhoI*        
  CC350              CTCGAGGTTGGTCGTATTTTGAAAATGCTGGAA        *XhoI*        
  CC351                  ATAGAGCATGTCATCCGCCAGCAC                           
  HY001                  AAGCTTAGTGCTGGCGATTGAGTCG           *Hin*dIII      
  YCC002                 ACTGGATCCTGCGACCGGAATAACC            *Bam*HI       
  **For qRT-PCR**        **Sequence (5′**→**3′)**        **TaqMan probes**   **Target**
  RT03                     CGTCATCCAGACCAAAGAGC                 83             *orf1*
  RT04                    CCGGTTTTTCAATAAACTCGAC                            
  RT05                     CGATGACCGGCTTTTTAATG                 83             *orf3*
  RT06                     CTAGCGGAGATTTGGTACTGC                            
  RT07                    CAGTCCACCTTTATTCCGATTG                67            *orf16*
  RT08                      AGGTACGACCCCGACTGG                              
  RT11                     GGTAGGGGAGCGTTCTGTAA                 67            23S rRNA
  RT12                     TCAGCATTCGCACTTCTGAT                             
  RT17                   TCAATAGCAATTAAGCACAAAAGAA              18             *rmpA*
  RT18                      TTGTACCCTCCCCATTTCC                             
  RT19                  AAATCATTACCCACAACTAACAAAAA              80            *rmpA2*
  RT20                    TTAGACGGCTTTTTAATTCATGG                           
  GT25                   AAAACAGAATCAAATATGCTGCAA               158            *rcsA*
  GT26                     CGTTGAGATTTGCGAAGTACC                            
  RT108                    AGCTGCTCTTCCGATCTTGA                 20             *cyaA*
  RT109                     AGCAGCTGACGCTCTTCG                              

Detection of cAMP {#s4b}
-----------------

Bacteria was adjusted to 1×10^7^ colony forming units (c.f.u.)/ml and washed twice in phosphate-buffered saline (PBS). Then, the bacteria were resuspended in 300 µl of 1X lysis buffer and lysated by sonication. The lysate was centrifuged briefly at 14,000 rpm for 10 min, and the supernatant was tested for cAMP levels by using cAMP XP™ Assay Kit (Cell Signaling Technology, Inc.) and according to manufacturer's recommendations.

Construction of the Gene-deletion Mutants and Complementation Plasmids {#s4c}
----------------------------------------------------------------------

Specific gene deletion containing *crp*, *cyaA*, and *cpdA* was introduced into *K. pneumoniae* CG43S3 using an allelic exchange strategy as previously described respectively [@pone.0054430-Lai1]. In brief, two approximately 1000 bp DNA fragments flanking both sides of the deleted region were cloned into the suicide vector pKAS46 [@pone.0054430-Skorupski2], a suicide vector containing *rpsL*, which allows positive selection with streptomycin for vector loss. The resulting plasmid was then mobilized from *E. coli* S17-1λ*pir* [@pone.0054430-Miller1] to *K. pneumoniae* CG43S3, *K. pneumoniae* CG43S3Δ*lacZ*, *K. pneumoniae* CG43S3Δ*rcsA* or CG43S3-derived strains, by conjugation. The transconjugants, with the plasmid integrated into the chromosome via homologous recombination, were selected with ampicillin and kanamycin on M9 agar plates. Several of the colonies were grown in LB broth supplemented with 500 µg/mL of streptomycin to log phase at 37°C and then spread onto an LB agar plate containing 500 µg/mL of streptomycin. The streptomycin-resistant and kanamycin-sensitive colonies were selected, and the deletion was verified by PCR and Southern hybridization (data not shown). The resulting *K. pneumoniae* mutants are listed in [Table 1](#pone-0054430-t001){ref-type="table"}.

To obtain the complementation plasmids, DNA fragments containing the promoter and coding sequence of *crp*, *cyaA*, and *rcsA* were individually PCR-amplified with primer pairs GT131/GT132, GT196/GT197, and HY001/GT145 ([Table 2](#pone-0054430-t002){ref-type="table"}) and cloned into the shuttle vector pACYC184 or pRK415 to generate pcrp, pcyaA, and prcsA, respectively. To generate the *cpdA* complement plasmid, pETQ-cpdA, DNA fragment containing the coding sequence of *cpdA* was individually PCR-amplified with primer pair GT210/211 ([Table 2](#pone-0054430-t002){ref-type="table"}) and cloned into the expression vector pETQ. To generate the His-*crp* complement plasmid, pETQ-His-*crp*, DNA fragment containing N-terminal His-tag fused with the coding sequence of *crp* was individually PCR-amplified with primer pair GT132/227 ([Table 2](#pone-0054430-t002){ref-type="table"}) from pET30b-CRP and cloned into the expression vector pETQ.

Extraction and Quantification of CPS {#s4d}
------------------------------------

CPS was extracted and quantified as previously described [@pone.0054430-Domenico1]. The glucuronic acid content, represents the amount of *K. pneumoniae* K2 CPS, was determined from a standard curve of glucuronic acid (Sigma-Aldrich) and expressed as micrograms per 10^9^ c.f.u. [@pone.0054430-Blumenkrantz1].

qRT-PCR {#s4e}
-------

Total RNAs were isolated from early-exponential-phase grown bacteria cells by use of the RNeasy midi-column (QIAGEN) according to the manufacturer's instructions. RNA was DNase-treated with RNase-free DNase I (MoBioPlus) to eliminate DNA contamination. RNA of 100 ng was reverse-transcribed with the Transcriptor First Strand cDNA Synthesis Kit (Roche) using random primers. qRT-PCR was performed in a Roche LightCycler® 1.5 Instrument using LightCycler TaqMan Master (Roche). Primers and probes were designed for selected target sequences using Universal ProbeLibrary Assay Design Center (Roche-applied science) and listed in [Table 2](#pone-0054430-t002){ref-type="table"}. Data were analyzed using the real time PCR software of Roche LightCycler® 1.5 Instrument. Relative gene expressions were quantified using the comparative threshold cycle 2^-ΔΔCT^ method with 23S rRNA as the endogenous reference.

Measurement of Promoter Activity {#s4f}
--------------------------------

The promoter-reporter plasmids, pRcsAZ15, pOrf12, pOrf315, and pOrf1617, were individually mobilized into *K. pneumoniae* strains by conjugation from *E. coli* S17-1 λ*pir*. The bacteria were grown to logarithmic phase in LB broth, and the β-galactosidase activity was measured as previously described [@pone.0054430-Lin2].

Identification of the Transcriptional Start Sites of Three Transcriptional Units in the K2 *cps* Gene Cluster {#s4g}
-------------------------------------------------------------------------------------------------------------

For the determination of 5′ mRNA ends in the three transcriptional units in the K2 *cps* gene cluster, a rapid amplification of PCR was performed using 5′ RACE kit (Clontech) according to the manufacturer's instruction as previously described [@pone.0054430-Cheng2]. A total of ten clones each of *galF*, *wzi*, and *manC*, respectively, were subjected to sequence analysis, and the transcriptional start sites of *galF*, *wzi*, and *manC* were determined. All the sequencing results indicated the same nucleotide as the transcriptional start site of *galF*, *wzi*, and *manC*.

Purification of His~6~-CRP Protein {#s4h}
----------------------------------

The coding region of *crp* was PCR amplified with primer sets GT132/GT137 ([Table 2](#pone-0054430-t002){ref-type="table"}) and cloned into the *Bam*HI/*Hind*III site in pET30b (Novagen, 205 Madison, Wis). The resulting plasmid pET30b-CRP was then transformed into *E. coli* BL21(DE3) (New England Biolabs), and overproduction of the recombinant protein was induced by the addition of 0.1 mM IPTG for 4 h at 37°C. The recombinant proteins were then purified from the soluble fraction of the total cell lysate by affinity chromatography using His-Bind resin (Novagen, Madison, Wis). Finally, the purified proteins were dialyzed against 1X TE buffer (20 mM Tris-HCl, pH 8.0, 1 mM EDTA) containing 10% glycerol at 4°C overnight, and the purity was determined by SDS-PAGE.

EMSA {#s4i}
----

The DNA fragments of the putative promoter region of *orf1-2*, *orf3-15*, *orf16-17*, and *rcsA* were respectively PCR amplified by using specific primer sets ([Table 2](#pone-0054430-t002){ref-type="table"}). The purified His~6~-CRP was incubated with 10 ng DNA in a 15 µl solution containing 4 mM Tris-HCl (pH 7.4), 10 mM KCl, 100 mM dithiothreitol, 200 µM cAMP, and 10 µg/ml BSA at room temperature for 30 min. The samples were then loaded onto a native gel of 5% nondenaturing polyacrylamide containing 200 µM cAMP in 0.5X TB buffer (45 mM Tris-HCl, pH 8.0, 45 mM boric acid). Gels were electrophoresed with a 20-mA current at 4°C and then stained with SYBR Green I dye (Invitrogen).

Bacterial Survival in Serum {#s4j}
---------------------------

Normal human serum, pooled from healthy volunteers, was divided into equal volumes and stored at −70°C before use. Bacterial survival in serum was determined with minor modifications [@pone.0054430-Lai1]. In brief, bacteria were grown in LB broth, and when growth reached mid-exponential phase, the bacteria were collected, washed twice with phosphate-buffered saline (PBS), and then adjusted to approximately 1×10^6^ c.f.u./ml. The reaction mixture containing 250 µl of the cell suspension and 750 µl of pooled human serum was incubated at 37°C for 15 min. The number of viable bacteria was then determined by plate counting. The survival rate was expressed as the number of viable bacteria treated with human serum compared to the number of pre-treatment. The assay was performed triple, each with triplicate samples. The data from one of the representative experiments are shown and expressed as the mean and standard deviation from the three samples. A CPS-deficient mutant strain, *K. pneumoniae* CG43S3Δ*galU* (*galU* encodes for an UDP-glucose pyrophosphorylase that is responsible for supplying UDP-glucose as material for CPS biosynthesis) is served as a control.

Statistical Method {#s4k}
------------------

An unpaired *t*-test was used to determine the statistical significance and values of *P*\<0.05 and *P*\<0.01 were considered significant. The results of CPS quantification, qRT-PCR analysis, and promoter activity measurement were derived from a single experiment representative of three independent experiments. Each sample was assayed in triplicate and the mean activity and standard deviation are presented.

Ethics Statement {#s4l}
----------------

For isolation of normal human serum from healthy volunteers, the procedure and the respective consent documents were approved by the Ethics Committee of the China Medical University Hospital, Taichung, Taiwan. All healthy volunteers provided written informed consent.

Supporting Information {#s5}
======================

###### 

**Glucose and cAMP affects the CPS levels of** ***K. pneumoniae*** **NTUH-K2044.** CPS levels of *K. pneumoniae* NTUH-K2044 were activated by increasing environmental glucose. Bacterial strains were grown in LB broth supplemented with glucose and cAMP as indicated at 37°C with agitation. After 16 h of growth, the bacterial glucuronic acid content was determined. \**P*\<0.05 and \*\**P*\<0.01 compared with no addition. \#*P*\<0.05 and \$ *P*\<0.01 compared to the indicated group.

(TIF)

###### 

Click here for additional data file.

###### 

**CRP directly binds to P** ***~galF~*** **.** Diagrammatic representation of the *galF* loci. The large arrows represent the open reading frames. The relative positions of the primer set used in PCR-amplification of the DNA probes are indicated, and the numbers denote the positions relative to the translational start site. Name of the DNA probes are shown on the left. Different concentrations of purified His~6~-CRP were incubated with 10 ng of the upstream regions of *galF*. Following incubation at room temperature for 30 min, the mixtures were analyzed on a 5% non-denaturing polyacrylamide gel containing 200 µM cAMP. The gel was stained with SYBR Green I dye and photographed.

(TIF)

###### 

Click here for additional data file.

###### 

**Induced expression of His~6~-CRP complements the effect of** ***crp*** **mutation on CPS biosynthesis.** CPS levels of *K. pneumoniae* strains carrying the IPTG inducible vector pETQ or pETQ-His*-crp*, as shown in the left panel, were determined. Bacteria were grown in LB medium with 100 µM IPTG at 37°C with agitation. \*\**P*\<0.01 compared to the indicated group.

(TIF)

###### 

Click here for additional data file.
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